Press Release
Luxembourg, December 1st 2020, Fareva Group has completed the acquisition of two sterile manufacturing sites located in Idron and Saint-Julien-en-Genevois (France) from Pierre-Fabre Group. This acquisition consolidate Fareva’s strategy to invest significantly into sterile area for the development and manufacturing of oncology products.
The Idron site (Pyrénées-Atlantiques area - close to Pau, France) has more than 200 employees with over 20 years of experience in manufacturing sterile injectable forms such as pre-filled syringes (PFS), lyophilized and liquid filled vials. The site includes 10 manufacturing workshops and a pilot plant that will be operational in 2022. The core business of the site is to handle highly potent and biologics products.
The Saint Julien-en-Genevois site (Haute Savoie area, France) is manufacturing monoclonal antibodies (MAB’s) with state-of-the-art single use bioreactor technology. In addition to manufacturing clinical batches, the site allows the purification and the coupling of monoclonal antibodies with high potent actives (up to OEB 6). This industrial platform will be monitored thanks to a strategic partnership with VBI Therapeutics – a company led by Alain Sainsot.
A broader sterile technology offering
These acquisitions will increase our sterile technology portfolio, to further develop highly-potent and biologic market segments. These two categories represent the majority of the new drugs applications launched in the market over the last 5 years.
Site of Idron
• > 200 employees
• Approved by Europe, USA Japan and Korea
• Freeze-dried vials ,Sterile Liquids and PFS
• Conventional injectables, biologic and high potent products
Site of St-Julien-en-Genevois
• >30 employees
• Approved by Europe
• Monoclonal antibodies and conjugated Monoclonal antibodies with high potent actives
Contact us for your future pharmaceutical projects at pharma@fareva.com
Fareva media contact
Marie Wicart, Communication Director
communication@fareva.com